www.dailypolitical.com ·
geovax labs nasdaqgovx announces quarterly earnings results 2
Topic context
This topic has been covered 239064 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedGeoVax Labs is a clinical-stage biotech company. The earnings beat is a company-specific event with no direct commercial mechanism for broader sectors. The stock price decline and low market cap indicate limited immediate commercial impact. No product revenue, supply chain, or scarcity signals are present.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- GeoVax Labs reported Q1 2026 EPS of ($2.62), beating consensus estimate of ($3.50) by $0.88.
- Shares fell 3.1% to $1.26 on May 14, 2026, with 125,676 shares traded.
- Market capitalization is $3.65 million; 12-month stock range $0.96 to $34.75.
- Institutional investors hold 6.09% of stock; recent stakes by Jane Street Group and Armistice Capital.
- Analyst ratings include 'strong sell' and 'hold'; average price target $150.00.
Related stories
finance.yahoo.com
ncmi q1 2026 earnings transcript 154748256
finance.yahoo.com
xponential xpof q1 2026 earnings 221145866
finance.yahoo.com
dxp dxpe q1 2026 earnings 215803136
economictimes.indiatimes.com
missiles over dubai rattle the gulfs billion dollar money machine dubai property uae deal ipo market
finance.yahoo.com